USA flag logo/image

An Official Website of the United States Government

Development of a Human Intraepithelial Cancer Model

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
53863
Program Year/Program:
2001 / SBIR
Agency Tracking Number:
1R43CA091607-01
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Stratatech Corporation
505 S. Rosa Road, Suite 169 Madison, WI -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2001
Title: Development of a Human Intraepithelial Cancer Model
Agency: HHS
Contract: N/A
Award Amount: $99,350.00
 

Abstract:

DESCRIPTION (PROVIDED BY APPLICANT): Over half of all human cancers occur in squamous epithelia. In order to enhance drug discovery for the treatment of squamous cell carcinoma (SCC) and other cancers, it is essential to have an organotypic in vitro model which recapitulates tumor and normal epithelial interactions. The Allen-Hoffmann laboratory recently developed an organotypic model that permits the assessment of tumor growth in stratified human squamous epithelia. The model is a co-culture of genetically marked human SCC cells and unmarked spontaneously immortalized human keratinocytes called NIKS cells. Unlike current in vitro assays, this model accounts for the influence of the normal tissue microenvironment (NTM) on the growth and differentiation of SCC cells. Another advantage is the model's relevance for other epithelial cancers (e.g., cervix, trachea) and its capacity for combination with other treatments (e.g., surgery, radiation). Our strategy for this proposal is to validate and optimize the organotypic co-cultures in the presence of known and novel anticancer agents (e.g., chemotherapeutics, cytostatic drugs) and quantify their effect on malignant cell growth by monitoring the genetically marked SCC cells. Pending completion of this Phase I work, we plan to develop a high-throughput, microliter-volume screening format to identify novel anti-tumor agents using the NIKS-based, human NTM tumor assay. PROPOSED COMMERCIAL APPLICATION: It is essential for effective durg discovery that in vitro models be able to test potential anticancer agents in a physiologically relevant context. Stratatech is developing products and services using a co-cultured system of genetically tagged squamous cell carcinoma (SCC) cells in an organotypic culture comprised of our propietary NIKS cell line. This model system represents a major technological advance for screening drugs or agents of potential use in treating cancers of the stratified squamous epithelia (e.g., head and neck, oral mucosa, cervix, trachea).

Principal Investigator:

Paul B. Conrad

Business Contact:


6084412750
AJB@STRATATECHSKINSCIENCE.COM
Small Business Information at Submission:

STRATATECH CORPORATION
UNIVERSITY RESEARCH PARK 505 S ROSA RD MADISON, WI 53719

EIN/Tax ID: 391977193
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No